secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001854270-24-000108
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio receives Nasdaq deficiency notice for audit committee composition
---------------------------------------------------------------------------

- On Oct 22, 2024, Nasdaq notified Senti Bio that its audit committee has only two members, violating Listing Rule 5605(c)(2)(A).
- Vacancy resulted from Susan Berland’s resignation from the board effective June 11, 2024.
- Cure period: until Dec 9, 2024 (since next annual meeting already held) or June 11, 2025, whichever earlier.
- No immediate impact on listing or trading of SNTI common stock on Nasdaq Capital Market.
- Company evaluating committee membership and intends to regain compliance before cure deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000108/0001854270-24-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000108/snti-20241022.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer